Prediction of Omeprazole Pharmacokinetics and its Inhibition on Gastric Acid Secretion in Humans Using Physiologically Based Pharmacokinetic-Pharmacodynamic Model Characterizing CYP2C19 Polymorphisms
- PMID: 37226024
- DOI: 10.1007/s11095-023-03531-y
Prediction of Omeprazole Pharmacokinetics and its Inhibition on Gastric Acid Secretion in Humans Using Physiologically Based Pharmacokinetic-Pharmacodynamic Model Characterizing CYP2C19 Polymorphisms
Abstract
Purpose: To develop a whole physiologically based pharmacokinetic-pharmacodynamic (PBPK-PD) model to describe the pharmacokinetics and anti-gastric acid secretion of omeprazole in CYP2C19 extensive metabolizers (EMs), intermediate metabolizers (IMs), poor metabolizers (PMs) and ultrarapid metabolizers (UMs) following oral or intravenous administration.
Methods: A PBPK/PD model was built using Phoenix WinNolin software. Omeprazole was mainly metabolized by CYP2C19 and CYP3A4 and the CYP2C19 polymorphism was incorporated using in vitro data. We described the PD by using a turn-over model with parameter estimates from dogs and the effect of a meal on the acid secretion was also implemented. The model predictions were compared to 53 sets of clinical data.
Results: Predictions of omeprazole plasma concentration (72.2%) and 24 h stomach pH after administration (85%) were within 0.5-2.0-fold of the observed values, indicating that the PBPK-PD model was successfully developed. Sensitivity analysis demonstrated that the contributions of the tested factors to the plasma concentration of omeprazole were Vmax,2C19 ≈ Papp > Vmax,3A4 > Kti, and contributions to its pharmacodynamic were Vmax,2C19 > kome > kms > Papp > Vmax,3A4. The simulations showed that while the initial omeprazole dose in UMs, EMs, and IMs increased 7.5-, 3- and 1.25-fold compared to those of PMs, the therapeutic effect was similar.
Conclusions: The successful establishment of this PBPK-PD model highlights that pharmacokinetic and pharmacodynamic profiles of drugs can be predicted using preclinical data. The PBPK-PD model also provided a feasible alternative to empirical guidance for the recommended doses of omeprazole.
Keywords: CYP2C19 polymorphism; PBPK-PD model; gastric acid secretion; omeprazole; turn-over model.
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers.Eur J Clin Pharmacol. 2010 Jun;66(6):563-9. doi: 10.1007/s00228-010-0821-6. Epub 2010 Apr 23. Eur J Clin Pharmacol. 2010. PMID: 20414645
-
Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people.J Clin Pharm Ther. 2007 Oct;32(5):517-24. doi: 10.1111/j.1365-2710.2007.00851.x. J Clin Pharm Ther. 2007. PMID: 17875119
-
The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.Clin Pharmacokinet. 2005;44(11):1179-89. doi: 10.2165/00003088-200544110-00005. Clin Pharmacokinet. 2005. PMID: 16231968
-
Clinical significance of the cytochrome P450 2C19 genetic polymorphism.Clin Pharmacokinet. 2002;41(12):913-58. doi: 10.2165/00003088-200241120-00002. Clin Pharmacokinet. 2002. PMID: 12222994 Review.
-
The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.Mol Diagn Ther. 2006;10(3):135-51. doi: 10.1007/BF03256453. Mol Diagn Ther. 2006. PMID: 16771600 Review.
References
-
- Howden CW, Holt S. Acid suppression as treatment for NSAID-related peptic ulcers. Am J Gastroenterol. 1991;86(12):1720–2. - PubMed
-
- Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP, Shimada T. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther. 1997;283(2):434–42. - PubMed
-
- Botton MR, Whirl-Carrillo M, Del Tredici AL, Sangkuhl K, Cavallari LH, Agúndez JAG, et al. PharmVar GeneFocus: CYP2C19. Clin Pharmacol Ther. 2021;109(2):352–66. https://doi.org/10.1002/cpt.1973 . - DOI - PubMed
-
- Hicks JK, Bishop JR, Sangkuhl K, Müller DJ, Ji Y, Leckband SG, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015;98(2):127–34. https://doi.org/10.1002/cpt.147 . - DOI - PubMed - PMC
-
- Simon T, Steg PG, Gilard M, Blanchard D, Bonello L, Hanssen M, et al. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French registry of acute ST-elevation and non-ST-elevation myocardial infarction (FAST-MI) registry. Circ. 2011;123(5):474–82. https://doi.org/10.1161/circulationaha.110.965640 . - DOI
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources